Tag: Astrazeneca
AstraZeneca: Failure of a phase III CALLA trial for Imfinzi
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
AstraZeneca: Evusheld approved in Covid prevention
(CercleFinance.com) – AstraZeneca announces that Evusheld (tixagevimab and cilgavimab) has been validated by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) as a pre-exposure prophylaxis treatment for COVID-19. 19.…
AstraZeneca: FDA requests more data on Fasenra
(CercleFinance.com) – AstraZeneca announces that the U.S. Food and Drug Administration (FDA) has issued a Comprehensive Response Letter (CRL) regarding the Supplemental Biologics License Application (sBLA) for Fasenra (benralizumab) how…
AstraZeneca: broker raises target to 10,500p
(CercleFinance.com) – The stock ends the session in the green as UBS reiterates its ‘buy’ recommendation on AstraZeneca while raising its price target from 10,000 to 10,500 pence, a new…
Market: AstraZeneca makes progress in its treatment of breast cancer
by Ludwig Burger (Reuters) – Pharmaceutical company AstraZeneca said on Monday its breast cancer treatment has been shown to be effective for women with a type of the disease for…
ASTRAZENECA: UBS favorable on the file
In a research note published by Michael Leuchten, the broker UBS advises to be interested in the title with a buying opinion.…
AstraZeneca: up 5%, an analyst’s favorite stock
(CercleFinance.com) – The stock rose by more than 5%, benefiting from the favorable analysis by Bank of America. The analyst firm renewed its buy recommendation on AstraZeneca, with a target…
AstraZeneca: Positive clinical trials on Lynparza
(CercleFinance.com) – AstraZeneca gained more than 2.5% on the British stock market on Tuesday after the announcement of the success of a clinical trial in the treatment of prostate cancer.…
AstraZeneca expects sales to accelerate in 2022
AstraZeneca expects sales to accelerate in 2022 | Photo credits: © AstraZeneca Feb 10 (Reuters) – AstraZeneca said on Thursday it expected higher sales in 2022 and raised its annual…
AstraZeneca: Orphan Drug Designation for Ionis
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
AstraZeneca: orphan drug designation for Ionis
(CercleFinance.com) – Ionis Pharmaceuticals announced on Monday that the US Food and Drug Administration (FDA) has granted orphan drug designation to eplontersen, its treatment for hereditary transthyretin (ATTR) amyloidosis, a…
AstraZeneca: increase in the production of the Covid vaccine
(CercleFinance.com) – The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) announces that it has approved the increase in manufacturing capacity of Vaxzevria, the…